When ever I see a new patient in oncology clinic I try to remind myself right before opening the clinic room door that today is likely one of the worst if not worst day in their life. Then I go in the room.

If you're a fan of SBRT for kidney cancer, please fill out this survey. Your replies will help us increase access to this non-operative treatment for patients worldwide. #radonc Shankar Siva Shankar Siva Anand Swaminath Matthias Guckenberger Matthew Katz, MD 🟦 docs.google.com/forms/d/e/1FAI…

The more things change, the more they stay the same #radonc #surgonc #takemyleftovers

I would like to thank all the patients, investigators, institutions, protocol team members, NRG Oncology, NCICancerTrials, and many others who helped with NRG LU002. We made incredible history in successfully randomizing to the largest OMD NSCLC trial to date evaluating local therapy

1)🚨Just out The Lancet - CURB randomized phase 2 RCT of SBRT for oligoprogressive metastatic NSCLC and breast cancer. thelancet.com/journals/lance… Simon Powell Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Biostatistics Service Radiation Medicine Program Radiation Oncology The Princess Margaret Cancer Foundation Princess Margaret Cancer Centre Jonathan Yang Isabel Preeshagul

"Judgmental or denigrating language when speaking to or about people living with #lungcancer or any other disease can undermine the emotional well-being of patients and is not consistent with modern, patient-centric medicine." Thanks Jill Feldman. iaslc.org/IASLCLanguageG…

🚨🚨🚨 EXTEND Trial Oligometastatic PDAC Randomized SOC vs +/- oligometastasis directed radiotherapy (MDT) 🔥 Addition of MDT improves PFS: 10.3 vs. 2.5 months, HR 0.43, p=0.03 👏🏽👏🏽 Ethan Ludmir MD and team!!! #GI24

1/N Finally out!! -- 30Gy for HPV+OPC in Journal of Clinical Oncology – work by the Memorial Sloan Kettering Cancer Center Head and Neck team, led by Nancy Lee, Eric Sherman, and myself on using hypoxia imaging response to cut treatment 60% (70->30Gy)! #radonc #hncsm ascopubs.org/doi/10.1200/JC…

🚨🚨🚨 Rectal Cancer Tweetorial!! Rectal cancer is a highly heterogeneous disease with rapid evolution in practice. Let's review current data to generate a pragmatic, patient-centric, approach to management! #GI24 #GIonc #RadOnc Thank you ASCO for the opportunity!🙏🏽 1/

Since the 21st Century Cures Act took effect, almost 80% of test results are viewed by patients with cancer before the ordering clinician, a doubling over the prior five years. ja.ma/3O7ZnU0

How to write an introduction section for a medical research manuscript

Vikram Jairam et al showing similarities between Flatiron Health database and CREST trial regarding differential benefit of consolidative thoracic RT in females vs. males with ES-SCLC Ben Slotman Anne Chiang Cary Gross Yale Radiation Oncology Residency Yale Cancer Center Yale COPPER Center doi.org/10.1016/j.adro…

Check out our work culminating in a web tool to predict the risk of brain metastasis in patients newly diagnosed with cancer! Paper: pubmed.ncbi.nlm.nih.gov/38388667/ Webtool: tinyurl.com/brain-mets Thanks to all of our collaborators especially Nicholas Zaorsky, MD MS and Ming Wang_CWRU!!

Updated Analysis of Comparative Toxicity of Proton and Photon Radiation for Prostate Cancer | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC… 11 years ago we published our findings of no difference. Given more time and more progress, we looked again… Cary Gross Yale COPPER Center

.Alexandra Potter led a study in Journal of Clinical Oncology showing that using smoking duration, instead of pack-years, to determine #lungcancerscreening eligibility is more equitable and greatly increases opportunities for early lung cancer detection. ascopubs.org/doi/10.1200/JC…

🔥🚨OncoAlert Hot Off the Press BIG NEWS Press Release by AstraZeneca #ADRIATIC phase 3 trial of #Durvalumab vs #Placebo after concurrent chemoradiotherapy in pts with limited-stage #SmallCell #LungCancer met dual primary endpoints of ⬆️#OS & ⬆️#PFS 👇🏼 astrazeneca.com/media-centre/p…

ARS Appropriateness Use Criteria for Unresectable Locally Advanced Non–Small Cell Lung Cancer Strong push for IMRT; discussion of nuances for PD-L1 negative / EGFR mutant / poor performance status or pulmonary function Kudos to George Rodrigues and Kristin Higgins! jamanetwork.com/journals/jamao…

NRG GU008 — an important trial for patients with node positive prostate cancer. Currently open and enrolling patients!

Limited stage small cell lung carcinoma treated with concurrent chemo-radiotherapy, adjuvant Durva IO improved OS and PFS, a new standard of care.

Burnout & moral injury in medicine have affected so many health care workers. As a mid-career physician, here’s what I’ve learned to combat it - I hope others find it to be helpful. In Search of Joy and Meaning in Modern Medicine JCO Oncology Practice ascopubs.org/doi/pdf/10.120…